[PRNewswire] Mylan Inc (NASDAQ:MYL) announced the U.S. launch of its Valsartan Tablets USP 40 mg, 80 mg, 160 mg, and 320 mg, which is the generic version of Novartis’ Diovan® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of hypertension, to lower blood pressure.(1)
Valsartan Tablets USP 40 mg, 80 mg, 160 mg, and 320 mg, had U.S. sales of approximately $2 billion for the 12 months ending September 30, 2014, according to IMS Health.To view the full article click here.
Mylan Inc (NASDAQ:MYL), On 10/30/2014, MYL reported 3 quarter 2014 earnings of $1.16 per share. This result was in-line with the consensus of the 11 analysts following the company and beat last year’s 3 quarter results by 41.46%. The next tentative earnings announcement is expected on 02/25/2015.
Insufficient price earnings data. MYL’s PE ratio is above average for the Biotechnology & Drugs industry and signals that investors are willing to pay a premium for this stock.
Mylan Inc (MYL)‘s PE ratio is among the lowest of any stock in the Semiconductors industry and signals that investors have not been willing to pay a premium for this company’s business prospects. Additionally, during the past year, earnings growth has outpaced its historical five year growth rate.
In terms of ratings, there are eighteen analysts that cover the stock which have provided Q4 2014 earnings per share estimates. The consensus anticipated number for the upcoming quarter is $1.04. The highest estimate is $1.09 while the lowest is $0.98. The company has a one year EPS growth rate of 3.69%.
Mylan Inc (MYL) is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Company’s generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Company’s API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.